Phase 2a将招募20名轻度至中度炎症患者，评估该产品的潜在疗效。患者将接受每日480 mg和960 mg的选定剂量。研究将测量血液中的炎症生物标志物，重点关注细胞因子、趋化因子和高敏C反应蛋白。

Pakistan's security forces have entered the final phase of their operation against terrorists who attacked a passenger train ...

"The extension of the first phase as proposed by the occupation is unacceptable to us, and the mediators and guarantor ...

周四，摩根士丹利重申对Vir Biotechnology（NASDAQ:VIR）股票的"增持"评级和20.00美元的目标价，较当前7.14美元的价格有显著上涨空间。根据InvestingPro数据，分析师目标价区间在14美元至110美元之间，反映出尽管近期市场面临挑战，但分析师对公司前景仍充满信心。该公司分析师强调，Phase 3 ECLIPSE试验已开始招募患者，标志着Vir ...